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ABSTRACT
In order for any function to occur within a cell, transcription factors must be able
to interact with genes. When this occurs, genes are expressed, and ultimately, proteins are
translated and perform the specific function that needs to be done within the cell. In order
for this to occur, genes must interact with transcription machinery. The Mediator complex
recruits transcription factors to genes in order to promote cell-type specific gene
expression. The Mediator complex is a multi-protein complex consisting of four modules:
head, middle, tail, and kinase. The kinase module is known to dissociate from the rest of
the complex in order to phosphorylate other proteins for the purposes of propagating
signals. MED12 of the kinase module has been shown to mediate CDK8 function by
binding to Cyclin C, allowing for phosphorylation and propagation of signals. Throughout
this thesis, I demonstrate MED12’s role in allowing CDK8 function in promoting cell-type
specific gene expression. Through the use of siRNA-mediated knockdowns of MED12, it
is evident that MED12 plays a role in the initiation of adipogenesis. qRT-PCR and staining
confirm this assumption, as there is significantly less adipogenesis occurring in hASCs
when MED12 is knocked down. This is further evidenced by reduced expression of early
adipogenic markers, most notably, PPAR-γ. If MED12 initiates cell type-specific gene
expression of differentiating adipocytes, then it may be used as a target to direct fat
formation to reduce the effects of obesity.
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CHAPTER 1
INTRODUCTION

1.1
1.1.1

Background

Obesity
Obesity-related deaths account for about 2.8 million deaths each year. These deaths

are an indirect result of excess fat accumulation, which leads to disorders like heart disease
and stroke (Obesity and Overweight, 2020). Obesity is defined as a body mass index (BMI)
greater than or equal to 30. There are three main classes of obesity. Classes I, II, and III
include those with BMIs up to 35, 40, or higher, respectively (Overweight & Obesity,
2021). A person with a BMI greater than 40 is considered to be extremely obese. The
Centers for Disease Control describes body mass index as an individual’s weight divided
by his or her height squared (kg/m²). Obesity is quickly becoming a serious problem in the
United States, as over 40% of the total US population is currently obese, including a
significant portion of the south (Figure 1-1). It disproportionately affects African
Americans and Hispanics, as well as those of lower socioeconomic status (Overweight &
Obesity, 2021). The obesity epidemic costs the US nearly $200 billion annually, with an
additional $1,500 per obese person in comparison to a non-obese person (Overweight &
Obesity, 2021).
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Figure 1-1: Prevalence of obesity in the United States (CDC, 2019).
1.1.2

Obesity Risk Factors
Factors that contribute to obesity include diet, exercise, cellular response to the

environment, and even genetics (Figure 1-2). As fast food and inexpensive processed
meals become more widely available, the population is showing exponential weight gain.
Therefore, researchers have recently been searching for a preventive therapy to treat
metabolic diseases in the hopes of someday controlling the obesity epidemic that is
currently plaguing our nation. Obesity is a growing problem across the globe, but most
notably in the United States as the population continues to gain weight and people develop
insulin resistance as a result (Smith & Kahn, 2016). Currently, most treatments for type II
diabetes treat the symptoms of the disorder through the use of insulin therapies by means
of painful injections and frequent finger pricking to monitor blood glucose levels. While
temporarily allowing for glucose uptake and decreasing blood glucose concentrations,
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researchers long for a permanent cure to the disease
(Smith & Kahn, 2016).

In order to understand how to

Cellular
Response

cure a disease like type II diabetes noninvasively,
researchers have turned to human adipose-derived stem

Diet

Exercise

cells to control fat production and maintenance of fat
masses in the body (Dean et al., 2020). If successful, researchers
may be able to control fat production in order to reduce the risk
of developing metabolic disorders resulting from excess fat

Figure 1-2: Factors
contributing to the
development of
obesity.

accumulation.

1.2
1.2.1

Adipogenesis

Adipose Tissue
In order for an individual to become obese, he or she must intake excess calories

and store the unused energy as fat in the body. Fat is used as a source of energy when the
body is fasting, but when fasting does not occur, fat continues to accumulate, leading to
weight gain. The process of forming new fat tissue is called adipogenesis (Smith & Kahn,
2016).
Typically, a healthy amount of adipose tissue is necessary for normal metabolic
function. Fat stores act as a protector of organs, as well as a ready store of free fatty acids
when glucose is not readily available. There are three main types of adipose tissue: brown,
beige, and white (Rosen & Spiegelman, 2014). They are classified based upon their
apparent visual appearances, the way the fat is distributed within the cells, as well as their
thermogenic potentials (Dean et al., 2020). Brown adipose tissue is more commonly found
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in juvenile animals, as it allows them to maintain body temperature before larger fat stores
are built. Beige adipose tissue is found in individuals chronically exposed to cold
temperatures. It is more thermogenic than white adipose tissue but less thermogenic than
brown adipose tissue. However, white adipose tissue is negatively associated with weight
gain and metabolic issues (Rosen & Spiegelman, 2014), making it the targeted tissue of
researchers hoping to downregulate fat formation in those suffering from obesity (Dean et
al., 2020). Fat tissue consists of adipocytes, pre-adipocytes, immune cells, fibroblasts, and
others, allowing it to secrete various hormones and cytokines, all of which have an effect
on the overall functioning of the human body (Chait & den Hartigh, 2020). Fat tissue is
capable of secreting inflammatory molecules like adipsin and TNF-α, as well as the
hunger-depressing hormone leptin (Rosen & Spiegelman, 2014).

1.2.2

Adipogenesis and Metabolism
Increased white adipose tissue deposits result in other metabolic issues throughout

the body. It has been shown that increased white fat storage increases inflammation in the
body through the recruitment of cytokine-secreting macrophages. In obese humans,
approximately 40% of adipose tissue was composed of macrophages compared to only
10% in individuals that had a normal BMI (Weisberg et al., 2003). This upregulated
inflammatory response has been connected to the development of type II diabetes in obese
individuals (Chait & den Hartigh, 2020).
Overall, the formation of adipose tissue is crucial to the development of obesity.
Like any function within the human body, adipogenesis requires a highly regulated network
of gene and transcription factor interaction. While several signaling pathways are involved
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in the process including the Wnt, BMP, and CEBPβ pathways, the peroxisome proliferatoractivated receptor gamma (PPAR-γ) is considered the master regulator of adipogenesis. It
serves as an early adipogenic marker and seems to be necessary for both initiation and
continuation of adipogenesis (Rosen & Spiegelman, 2014). When studying stem cells,
PPAR-γ is monitored to determine when adipogenesis starts and to what extent it is
occurring. The only way for researchers to observe differentiation, and therefore the
adipogenic process, is through the use of stem cells.

1.3
1.3.1

Stem Cells and Adipogenesis

Stem Cell Properties
Stem cells have two defining properties: the ability to differentiate down a specified

lineage or self-renew (Fuchs & Chen, 2013; Zuk et al., 2002). Stem cells can be totipotent,
pluripotent, and multipotent. Totipotent cells are capable of differentiating into any
embryonic cell, as well as any extraembryonic cell, including but not limited to, the
placenta and umbilical cord. Pluripotent stem cells differentiate into any cell of the embryo,
while multipotent stem cells are capable of differentiating into any cell of a specific cell
lineage (Watt & Driskell, 2010). Once a cell begins the differentiation process, it cannot
change back into a stem cell, nor can it change its future fate; it is committed (Smith &
Kahn, 2016).
1.3.2

Types of Stem Cells
There are three main types of stem cells: embryonic, induced-pluripotent (iPS), and

adult stem cells. Embryonic stem cells are pluripotent in nature. They can differentiate into
any cell of the embryo and are therefore extremely valuable. However, embryonic stem
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cells can only be harvested from blastocysts, as they are not found in adults. This process
of destroying an embryo for stem cells is highly controversial. As a result, researchers have
turned to the more widely available adult stem cells (Yu & Thomson, 2016).
Induced pluripotent stem cells are somatic cells that have been forced to return to
a stem-like state. Researchers often use viral vectors to convert adult cells into pluripotent
stem cells that are capable of differentiating down specific cell lines for regenerative
medicine purposes. These cells are induced to differentiate by cell type-specific
transcription factors (Ye et al., 2013). The first induced pluripotent stem cells used
fibroblast cells and the resulting iPSCs was identical to an embryonic stem cell (Takahashi
& Yamanaka, 2006).
Adult stem cells are multipotent in nature. They can differentiate into cells of
specific cell lineages, more specifically those of the endoderm, mesoderm, or ectoderm.
Multipotent stem cells possess the ability to self-renew and are capable of differentiating
down specified lineages. Multipotency and self-renewal allow stem cells to replenish
damaged tissue while also maintaining a population of stem cells (Fuchs & Chen, 2013).
Differentiation is necessary for formation of new tissue in utero, as well as promoting the
proliferation of new tissue during growth. Both differentiation and self-renewal are crucial
to the development of an individual (Fuchs & Chen, 2013). Self-renewal is an important
property of adult stem cells, but it is limited. Once self-renewal has been exhausted, and
cells begin to senesce, aging occurs (J. Liu et al., 2020). This process is highly regulated,
and if mutation causes more rapid self-renewal, or if injury, aging, or demand on cells is
too much, stem cell regeneration will be depleted too quickly, leading to a multitude of
other problems, including degeneration, atrophy, and cancer (Fuchs & Chen, 2013).
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1.3.3

Mesenchymal Stem Cells
Mesenchymal stem cells are a class of multipotent cells that can differentiate into

any cell type found in the mesoderm layer of the human body, including osteocytes,
adipocytes, myocytes, and chondrocytes (Eto et al., 2018) (Figure 1-3). Mesenchymal
stem cells are of increasing therapeutic interest because of their regenerative capacity and
wide differentiation potential. Human adipose-derived stem cells, or hASCs, are a type of
multipotent mesenchymal stem cell. They are relatively easy to harvest when compared to
stem cells derived from bone marrow, which involves an invasive procedure with a low
cell survival rate following transplantation. Human ASCs, on the other hand, can be
extracted from adipose tissue through a minimally invasive liposuction procedure (Aust et
al., 2004), and are able to be stored for future use through cryopreservation (Escobar &
Chaparro, 2016). Since hASCs are found in adults and are easily accessible, the
controversy regarding their use is greatly reduced when compared to the use of embryonic
stem cells. In addition, host rejection occurs less frequently since the host and recipient are
the same, thereby reducing the risk of graft-versus-host disease, or GVHD (Marks et al.,
2016). Therefore, it is evident that adipose-derived stem cells play a vital role in the future
of regenerative medicine.
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Figure 1-3: Mesenchymal stem cells are capable of differentiating into any cell of the
mesoderm: adipocytes, myocytes, osteocytes, and chondrocytes (Eto et al., 2018).

1.3.4

Clinical Use
Currently the FDA has only approved clinical use of hematopoietic and osteogenic

stem cells (Marks et al., 2016) due to lack of sufficient research regarding the use of other
stem cells. In 2018 alone, there were nearly five thousand hematopoietic stem cell
transplants in the United States to treat cancers of the blood and bone (Marks et al., 2016).
Hematopoietic stem cells are multipotent in nature, meaning they are capable of
differentiating into several different types of cells all within the blood cell lineage. Stem
cells can be transplanted from an autologous or allogenic source, but autologous
implantation has proven most successful due to GVHD (Marks et al., 2016). The success
of hematopoietic stem cells has led researchers to begin studying other types of adult stem
cells, including mesenchymal stem cells, which show great promise in the clinic.
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Stem cell research and regenerative medicine are areas of great interest in the
biomedical community as debilitating conditions like obesity continue to prevent patients
from performing optimally, and ultimately lead to other serious health conditions like type
II diabetes (Smith & Kahn, 2016). By targeting adipogenic markers in adipose-derived
stem cells and differentiated adipocytes, fat development can be controlled (Dean et al.,
2020). If we can prevent unwanted fat from developing or downregulate its production,
then we may be able to avoid or at least mitigate some of the complications that arise from
obesity, including diabetes.
Stem cells have been used to treat some diseases in the past, and as research
continues, their use is becoming more widespread. If successful, stem cells can be used to
treat a larger population and possibly more diseases that affect a greater number of
individuals. hASCs are being studied thoroughly for their potential in the treatment of
degenerative conditions that affect tissues of the mesoderm such as muscle, cartilage, and
even bone (Eto et al., 2018). As of 2013, there were over 300 clinical trials testing the
application of mesenchymal stem cells (Wei et al., 2013). Mesenchymal stem cells have
been induced to form functioning cardiac tissue (Choi et al., 2010) and been shown to yield
positive results in treating the symptoms of MS (Stepien et al., 2016). Multiple sclerosis is
an autoimmune, degenerative disease of the nervous system, where the central nervous
system attacks the nervous tissue, causing severe inflammation and irreversible scarring,
leaving the patient’s nervous system permanently damaged (What Is MS?, 2020). Due to
the ability of adipose-derived stem cells to evade immune response, they are an ideal
candidate for treating this disease, as the immune system is unable to attack them as
effectively as the nervous tissue (Stepien et al., 2016).
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Human ASCs have also been used in cosmetic surgeries and may ultimately give
further insight into reconstructive surgeries for patients suffering from tissue loss
(Yoshimura et al., 2008), similar to those being discussed to treat osteoarthritis of the joints.
1.3.5

Treatments for Metabolic Disorders
Stem cells have been used to treat some diseases in the past, and as research

continues, their use is becoming more widespread. However, for stem cell use to reach its
full potential, researchers aim to find a cure to more widespread diseases, like obesity. If
successful, stem cells can be used to treat a larger population and possibly more diseases
that affect a greater number of individuals.
In addition to the potential role of mesenchymal stem cells in regenerative
therapies, they show great potential in treating metabolic diseases as well. Obesity and
diabetes are related, as those suffering from obesity have an increased risk of developing
insulin resistance. Fat tissue has been shown to regulate insulin sensitivity, but when fat is
in excess, this process is severely downregulated in some patients (Smith & Kahn, 2016).
Obesity also increases the risk for cardiovascular diseases (Carbone et al., 2019) many of
which can result in myocardial infarction if left untreated. In the instance in which
infarction occurs, mesenchymal stem cells have been shown to form functioning
cardiomyocytes (Choi et al., 2010) clearly indicating another possible use as a regenerative
therapy.
If researchers find evidence to suggest that controlling hASC fate reduces or even
eliminates the effects of obesity, then there will be no end to the capabilities of stem cells.
Decreasing the number of obese individuals will reduce the harsh financial burden on the
US, and the medical field will have a significant reduction in the number of obesity-related
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deaths and diseases. Therefore, researchers aim to find a non-invasive, universal cure to
metabolic disorders through the use of stem cells. The first step towards this goal is to
determine how to control cell type-specific gene expression and stem cell fate.

1.4
1.4.1

Regulators of Cell Fate

Transcription
In order to maximize the potential of stem cells in the clinic, we need to have a

better understanding for how the environment, signaling pathways, and transcription
factors all work together to control cellular differentiation (Figure 1-4). Any external
stimulus is capable of initiating a signaling cascade that leads to the modification of
chromatin and the activation of genes, directing transcription and ultimately leading to the
production of protein. The newly available proteins will perform functions throughout the
cells to produce an effect, such as differentiation of stem cells into adipocytes.
Transcription factors are capable of modifying chromatin by directly binding to DNA and
are directed to the specific portion of DNA that needs modifying by a number of factors
(Latchman, 1993). Once at specified genes, transcription factors need to be able to
communicate with the transcriptional machinery. In order to do this, there must be a
modulator between cell type-specific genes and RNA Polymerase II (Allen & Taatjes,
2015).
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Figure 1-4: A variety of factors work together to control gene expression. External stimuli
direct chromatin modifications, activate signaling pathways, and influence transcription
factor activity. Acetylation and methylation modify chromatin by promoting the formation
of euchromatin and heterochromatin, respectively. Transcription factors are proteins
capable of binding to DNA at genomic enhancers and transcriptional promoters in order to
activate transcription (Latchman, 1993) by RNA Polymerase II (Allen & Taatjes, 2015).
This chain reaction of activating or silencing gene expression is what specifies cell fate.
1.4.2

The Mediator Complex
Mediator, a multi-unit protein complex, connects cell-type specific transcription

factors to RNA Polymerase II at the promoter, thereby initiating gene expression from
distal enhancer elements (Allen & Taatjes, 2015). Mediator is highly conserved among
species and consists of four subunits: head, middle, tail, and kinase (Figure 1-5). The
kinase module is made of four subunits: MED12, MED13, CDK8, and Cyclin C and can
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dissociate from core Mediator through MED13 association, allowing it to function
separately from the entire complex. Prior research shows that MED12 plays a role in the
activation of CDK8 by binding to Cyclin C. When this interaction is interrupted, CDK8 is
unable to phosphorylate proteins (Allen & Taatjes, 2015). When phosphorylation does not
occur, then signal cascades cannot be propagated, preventing downstream effects like
differentiation. Although it is clear that Mediator plays a role in regulation of transcription,
there is much left to be uncovered. Further study of this complex and the role it plays in
regulating cell-type specific gene expression is critical to the advancement and application
of stem cells in the clinic. Therefore, studying MED12’s role in gene regulation will give
insight into its stem cell application.

Figure 1-5: The Mediator Complex is highly conserved among eukaryotic species. More
complex organisms have paralogues to several subunits of Mediator, most notably, kinase
module paralogues: MED12L, MED13L, and CDK19 (Allen & Taatjes, 2015).
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1.5
1.5.1

Mediator and Cell Type-Specific Gene Expression

The Mediator Complex Function
The Mediator complex has been shown to promote cell type-specific gene

expression by acting as a bridge between genes and transcription machinery (Figure 1-6).
MED12 specifically initiates this process by activating CDK8, a kinase known to
phosphorylate proteins involved in the transcription cascade for gene expression (Allen &
Taatjes, 2015). Interestingly, MED12 mutations cause severe developmental delays by
decreasing expression of nearby genes due to the inability to bind to non-coding RNAs.
When this occurs, Opitz-Kaveggia syndrome results, and the individual is severely
debilitated (Lai et al., 2013). Other developmental disorders directly result from MED12
mutations including Lujan and Ohdo syndromes, both of which are X-linked traits as
MED12 is found on the X chromosome. These two syndromes result in the inability to
propagate the Shh signaling cascade, resulting in the inhibition of proper nervous system
development (Srivastava et al., 2019).

.
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Figure 1-6: The Mediator complex acts as a bridge between cell type-specific genes and
transcription machinery, allowing for gene expression.

MED12 is also mutated in most uterine leiomyomas, leading researchers to believe
it may be a target for treating these cancers. When MED12 is mutated, Cyclin C can no
longer bind to it, resulting in the inability of CDK8 to function. As a result, signals are not
propagated properly, and tumors result (Turunen et al., 2014). Because of this, researchers
are looking to target the interaction between MED12 and Cyclin C in order to prevent this
disrupted interaction when MED12 is mutated.

1.5.2

Mediator and Mammalian Development
In addition to the work done on MED12, other subunits have already been

implicated in cellular differentiation and adipogenesis. MED28 knockdown resulted in
severe inhibition of peri-implantation in embryonic mice, proving MED28’s role in
mammalian development and furthering the argument for Mediator’s role in growth and
differentiation of tissues (Li et al., 2015). Similar to MED28, research suggests that
MED19 plays a role in development of fat tissue. MED19, a core Mediator subunit, is
required for the formation of white adipose tissue by bridging PPAR-γ (the master regulator
of adipogenesis) to RNA Pol II for transcription of cell type-specific genes. When MED19
is absent, this specific transcription cannot occur (Dean et al., 2020).
Though MED28 and MED19 are part of core Mediator, they both play a role in
neuronal-specific gene expression through aiding the binding of Mediator to promoter
regions (Ding et al., 2009; Immarigeon et al., 2020; J. Yin & Wang, 2014). MED19 has
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even been shown to allow for MED12 and MED13 interaction with core Mediator even
when Cyclin C and CDK8 have been knocked down (Tsai et al., 2013).
The research on MED28 and MED19 and their role in mammalian development
suggests that other subunits in the complex may also have a critical function in regulating
cell state. If MED12 plays a role in adipogenic gene expression during differentiation, then
MED12 may also be an important target for directing stem cell fate to inhibit development
of obesity and the diseases that directly result from it.

CHAPTER 2
RESULTS

2.1

Characterizing Adipogenesis and Profiling MED12 Expression

In order to determine the profile of MED12 expression during adipogenesis, we
first needed to demonstrate successful differentiation of hASCs. We induced adipogenesis
and monitored it over a fourteen-day time period to confirm lipid droplet formation.
Following characterization of adipogenesis, we monitored MED12 transcript and protein
expression at times that matched significant differentiation events: three, seven, and
fourteen days. We observed that MED12 expression decreases as adipogenesis progresses,
while PPAR-γ expression increases over time.

2.1.1

Baseline MED12 Expression
In order to detect MED12, we used self-renewing cells to optimize conditions for

protein expression (Figure 2-1).

Figure 2-1: Baseline expression of MED12 protein using Tubulin1-α as a loading control
(L: ladder, S: sample).
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2.2

Characterization of Adipogenesis

In order to understand how MED12 affects fat formation, we first characterized
normal adipogenesis (Figure 2-2).

Figure 2-2: Human adipose-derived stem cells at 10x magnification prior to adipogenic
induction.

Cells were induced to differentiate and then imaged three, seven, and fourteen days
later (Figure 2-3). As early as seven days, lipid vesicles were observed with significantly
more present at the end of fourteen days.

Figure 2-3: Human adipose-derived stem cells three, seven, and fourteen days after
inducing adipogenic differentiation. Phase contrast images taken at 4x magnification.
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After visually confirming that adipogenesis was occurring, RT-PCR was performed
to determine changes in expression of MED12 and PPAR-γ, of which PPAR-γ is shown to
increase throughout this differentiation process (Figure 2-4).

100 bps

Figure 2-4: PPAR-γ expression (70bps) zero, three, seven, and fourteen days
after inducing adipogenesis. Samples collected in triplicate.
2.3

Oil Red O Optimization for Characterizing Adipogenesis

A standard measure of adipogenesis is Oil Red O staining and quantification. In
order to achieve high quality staining, our Oil Red O protocol required initial optimization.
Initially, hASCs were stained seven days after inducing adipogenesis. Lipid
droplets were unstained when viewed using the Cytation 5 BioTek plate reader, despite
obvious lipid droplet formation in the phase contrast images (Figure 2-5).
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Figure 2-5: hASCs stained seven days after inducing adipogenesis. Lipid droplets were
unstained, despite evident lipid droplet formation in the phase contrast images.

After purchasing new Oil Red O stain and making the stock solution from scratch,
lipid droplets were stained, but failing to filter the solution before staining resulted in
significant background and clumps of Oil Red O stain precipitate. Figure 2-6 shows
hASCs three days after inducing adipogenic differentiation where undissolved Oil Red O
floated to the top of the PBS suspension, leaving a shadow over the stain. Although the
stain is present, large pieces of undissolved stain sank to the bottom of the wells, making
the image unusable.
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Figure 2-6: hASCs stained three days after inducing differentiation. Lipid droplet
staining is evident, but Oil Red O precipitate made the images unusable.

Cells were cultured again, induced to differentiate, and stained (Figure 2-7). Using
the new stain and proper filtering, the lipid droplets were stained without any unfiltered
precipitate. The hASCs shown below were stained fourteen days after adipogenic
induction, and clear lipid droplet staining is evident.

Figure 2-7: hASCs stained fourteen days after inducing adipogenic differentiation.
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2.4
2.4.1

Knockdown of MED12 Results in Decreased Adipogenesis Over Time
Transcript Expression
Observing that MED12 expression decreases with PPAR-γ expression during

adipogenesis, we then wanted to determine how decreasing MED12 expression affected
adipogenesis and therefore PPAR-γ expression.
Upon culturing, knocking down MED12 and inducing adipogenesis the following
day, cells were collected at three, seven, and fourteen-day timepoints. RNA was extracted
to validate knockdown of MED12 and expression of PPAR-γ was examined to evaluate the
influence of this knockdown on adipogenesis. qRT-PCR indicates transcript expression at
the indicated timepoints, where MED12 knockdown confirmed to decrease by 97.4%,
96.6%, and 88.0% after three, seven, and fourteen days of adipogenesis, respectively
(Figure 2-8, Figure 2-9, and Figure 2-10). PPAR-γ expression decreased significantly
until day fourteen.

Figure 2-8: MED12 and PPAR-γ expression three days after inducing adipogenic
differentiation. Data was normalized to Tubulin1-α and samples were analyzed in
triplicate.
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Figure 2-9: MED12 and PPAR-γ expression seven days after inducing
adipogenic differentiation. Data was normalized to GAPDH and samples were analyzed
in triplicate.

Figure 2-10: MED12 expression fourteen days after inducing adipogenic
differentiation. Data was normalized to GAPDH and samples were analyzed in
triplicate.

2.4.2

Oil Red O Staining

Based upon relative expression of MED12 and PPAR-γ, it is evident that a decrease in
MED12 expression results in decreased expression of adipogenic markers. Therefore,
knockdown of MED12 inhibits adipogenesis from occurring as efficiently. In order to
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further investigate this phenomenon, it was necessary to visualize the cells at each
timepoint when MED12 expression was decreased (Figure 2-11).
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Figure 2-11: Scrambled siRNA and MED12-specific siRNA hASCs stained
seven days after inducing adipogenic differentiation. Cells are shown in both phase
contrast and color, at 4x and 10x magnification.
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Based on Oil Red O staining, it seems that decreased expression of MED12
decreases the amount of fat formation that can occur through day seven after induction.
However, although lipid vesicle formation is inhibited seven days into differentiation,
we wanted to determine if the same was occurring late into adipogenesis. Therefore,
we performed the same experiment, but waited until fourteen days after inducing
adipogenesis to stain the cells with Oil Red O (Figure 2-12).
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Figure 2-12: Scrambled siRNA and MED12-specific siRNA hASCs stained
fourteen days after inducing adipogenic differentiation. Cells are shown in both phase
contrast and color, at 4x and 10x magnification.
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As suggested by the cells stained seven days after inducing differentiation, the
same conclusions were drawn from the fourteen-day stains. Decreasing MED12
expression before inducing adipogenesis seemed to limit the lipid formation process.
However, the only way to be certain if there is a significant difference in the amount of
stain present between the negative control and knockdown samples was to perform a
stain extraction of the cells (Figure 2-13). The stain extraction indicates that there is
significantly less lipid present, and therefore less adipogenesis occurring, when MED12
expression is diminished. Although PPAR-γ expression is upregulated at this timepoint,
this may a result of diminished expression to this point, and therefore compensation for
loss of MED12 expression.
There is in fact a significant difference in the amount of Oil Red O stain present
in the MED12 knockdown cells versus the scrambled siRNA cells. These results
indicate a significant decrease in lipid vesicle formation and Oil Red O staining when
levels of MED12 are significantly decreased.
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Figure 2-13: Oil Red O stain extraction fourteen days after inducing
adipogenic differentiation.

2.5

Delayed Knockdown of MED12 Post-Adipogenic Differentiation has
Minimal Effect on Adipogenesis of hASCs
As shown previously, MED12 seems to play a role in initiating the transcription

of cell type-specific genes, as expression typically decreases over time as adipogenesis
progresses. In order to provide further evidence for MED12’s role in early
differentiation or to determine where specifically in differentiation MED12 has a role,
we performed a delayed knockdown study, reducing the expression of MED12 three
and seven days after inducing adipogenesis (Figure 2-14).
The first groups of cells were transfected with MED12-specific siRNA prior to
adipogenic differentiation, the second group was transfected with siRNA three days
into the adipogenic process, and the final group was transfected with siRNA seven days
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into adipogenesis. All RNA and protein samples were collected fourteen days after
induction of differentiation.

Figure 2-14: Experimental setup of delayed knockdown experiments.

MED12 knockdown was validated using endpoint PCR, qRT-PCR, and western
blots, all of which indicated knockdown of MED12 for all three timepoints.

2.5.1

MED12 and PPAR-γ Transcript Expression
Given our uncertainty about efficiency of knockdown during adipogenesis, we

first performed RT-PCR to see if we could observe decreased MED12 transcript at each
time point (Figure 2-15). Indeed, we saw that when MED12 siRNA is present, MED12
transcript is expressed at significantly lower levels when compared to the negative
control samples.
PPAR-γ expression is not significantly higher or lower in the MED12
knockdown samples for all three timepoints as well, indicating that adipogenesis is
minimally affected by a decrease in MED12 expression. This may suggest that MED12
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is not required later in adipogenesis, but only in the earlier stages of cell fate
commitment.
The apparent increase in PPAR-γ expression when MED12 is knocked down
seven days after inducing adipogenesis may suggest a compensatory role of the
adipogenic marker to maintain adipogenesis when MED12 is depleted.

100 bps

Figure 2-15: MED12 (87 bps) expression after knocking down (KD) one day
prior to the differentiation process (PD), and three (3d) and seven (7d) days after
inducing adipogenesis, using GAPDH (99 bps) as a loading control.

Following confirmation of knockdown, we wanted to quantify any changes in
MED12 expression. Gene expression of MED12 and PPAR-γ was determined using
qRT-PCR at each timepoint (Figure 2-16, Figure 2-17, and Figure 2-18).
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Figure 2-16: Pre-differentiation Knockdown qRT-PCR. Data was normalized
to GAPDH and samples were analyzed in triplicate.

Figure 2-17: Day 3 Delayed Knockdown qRT-PCR. Data was normalized to
GAPDH and samples were analyzed in triplicate.
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Figure 2-18: Day 7 Delayed Knockdown qRT-PCR. Data was normalized to
GAPDH and samples were analyzed in triplicate.

2.5.2

MED12 and PPAR-γ Protein Expression
We further validated our observations by evaluating protein expression, as this

does not always match transcript expression. MED12 protein expression is significantly
lower in the MED12 knockdown samples versus the negative control samples when
knockdown was performed one day prior to inducing adipogenesis (PD), as well as
three (3d) and seven (7d) days after inducing adipogenesis. Using the same timepoints
as before, protein expression of MED12 and PPAR-γ during MED12 knockdown
compared to normal MED12 expression was determined during adipogenesis, using
GAPDH as a loading control (Figure 2-19). PPAR-γ is shown as two separate bands in
the western blot: one band at 53 kDa and another at 57 kDa. This is due to the nonspecificity of the PPAR-γ antibody resulting in detection of both PPAR-γ1 and PPARγ2 (M. C. Liu et al., 2020). MED12 evidently affects expression of other proteins as
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well, evidenced by decreased expression of GAPDH. However, Image J analysis needs
to be performed to confirm if this change is in fact significant.

Figure 2-19: MED12 and PPAR-γ protein expression when MED12
expression is decreased one day prior to inducing adipogenesis (PD), and three (3d)
and seven (7d) days after inducing adipogenic differentiation. All cells were collected
fourteen days after inducing adipogenic differentiation (L: ladder, NC: negative
control, KD: knockdown).

After confirming efficient knockdown, we sought to evaluate adipogenesis in
each of these knockdown assays. PPAR-γ expression significantly decreased from the
negative control to the knockdown samples when knockdown of MED12 was
performed both one day prior to inducing adipogenesis, as well as three days after
inducing adipogenesis. However, PPAR-γ expression was comparable between
negative control and knockdown samples when knockdown was performed seven days
after inducing adipogenesis. This suggests that MED12 may play a role in early
adipogenesis, but its absence late in adipogenesis has little effect on continuing fat
formation. However, PPAR-γ transcript and protein expression conflict. Transcript
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shows increased expression in the MED12 knockdown cells for all delayed
knockdowns, but protein expression shows significant downregulation when MED12
is knocked down during adipogenesis.

2.5.3

Delayed Knockdown Oil Red O Staining
Following observations of changes in gene and protein expression, we wanted

to visualize the change in adipogenesis through the use of Oil Red O staining.
Using the same timepoints as before, lipid droplets in hASCs were stained with
Oil Red O after 14 days of adipogenesis with MED12 siRNA transfections having taken
place one day prior to inducing adipogenesis, three days after inducing adipogenesis,
and seven days after inducing adipogenesis (Figure 2-20).

Figure 2-20: Oil Red O staining of hASCs when MED12 is knocked down one day
prior to inducing adipogenesis and three and seven days after inducing adipogenesis.
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A stain extraction was performed to quantify the differences in stain present
between the negative control and knockdown samples (Figure 2-21). The Oil Red O
stain extraction indicates more lipid droplet formation in the negative control
knockdown versus the MED12 knockdown samples when knockdown was performed
one day prior to adipogenic induction (PD), as well as three days after adipogenic
induction (Day 3). However, lipid droplet formation was comparable between the
negative control and MED12 knockdown samples when knockdown was performed
seven days after inducing adipogenesis. Consistent with the protein expression studies,
this gives indication that MED12 is required for initiating adipogenesis but may not
play a role in late adipogenesis.

Figure 2-21: Delayed MED12 knockdown experiments Oil Red O stain extraction
when MED12 is knocked down one day prior to inducing adipogenesis (PD) and three
(Day 3) and seven (Day 7) days after inducing adipogenic differentiation.

37

2.6

Conclusion

MED12 plays a crucial role in transcription of cell type-specific genes. Previous
research suggests that MED12 mutation results in uterine leiomyomas, X-linked
developmental disorders, and even disruption of the Shh signaling cascade. All of these
disorders directly result in interruption of normal developmental processes. Given the
importance of adipogenesis in development and the role it plays in disease, we sought
to determine how decreasing expression of MED12 affects adipogenesis of hASCs.
When MED12 is present, hASCs differentiate to their full potential, and when MED12
expression is decreased before inducing adipogenesis, differentiation is diminished.
When profiled over time, MED12 expression was observed to decrease following the
induction of adipogenesis, indicating a more crucial role in early adipogenesis. This is
confirmed by prior research in the lab (Allen and Taatjes, 2015), as MED12 has been
shown to initiate transcription, while adipogenic markers like PPAR-γ remain present
and active throughout differentiation.
When MED12 is knocked down later in adipogenesis, it seems to play less of a
role, as PPAR-γ transcript is not significantly affected by decreasing MED12
expression seven days after the induction of adipogenesis, and in some cases, it even
increases in expression, possibly to compensate for loss of MED12 function. However,
protein expression of PPAR-γ did not follow the same trend. PPAR-γ showed
significant downregulation when MED12 expression was decreased one day prior to
inducing adipogenesis, as well as three days after inducing adipogenesis, but not seven
days post-induction. This observation was confirmed through Oil Red O stain

38
extraction, suggesting that adipogenesis is significantly inhibited when MED12 is
knocked down before adipogenesis, as well as three days after beginning the process,
but not seven days after inducing.
Overall, it is evident that MED12 plays a role in early differentiation of hASCs.
MED12’s responsibility in activating CDK8 through Cyclin C binding is crucial to cell
type-specific gene expression. Interruption of this interaction downregulates
transcription, providing evidence that complete knockout of MED12 likely prevents
cell type-specific transcription from occurring at all.
If this is true, then MED12 is a potential target for stem cell therapies, like those
currently being researched for ending the obesity epidemic. If so, then fat cell formation
can be controlled in order to direct it to become browner in nature, thereby promoting
thermogenesis, or prevent white fat from forming, resulting in decreased effects from
fat accumulation. If this is possible, then we can prevent obesity-related diseases from
plaguing our world, and the obesity epidemic will be cured by a non-invasive,
minimally invasive, genomic means.
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CHAPTER 3
METHODS

3.1
3.1.1

Cell Culture

Complete Culture Media (CCM)
Prior to making media, MEM Alpha (1X) (ThermoFisher Scientific 12561049),

fetal bovine serum (FBS) (Atlanta Biologicals S11550), 200mM L-Glutamine (L-Glut)
(Gibco 25030-081), and pen strep were warmed to 37°C. Using a 250 mL Corning filter
system (VWR 28199-770) under a sterile hood, 203.75 mL MEM Alpha (1X), 41.25 mL
FBS, 2.5 mL L-Glut, and 2.5 mL pen strep were mixed and filtered. Media was stored at
4°C for up to two weeks.
3.1.2

Thawing Adipose Stem Cells
Cells were thawed in a 37°C water bath before being transferred to pre-warmed

CCM. Cells were centrifuged at 1,500 RPM and then resuspended in CCM. The cells were
plated onto a 10 cm tissue culture-treated plate. The following day, media was changed.
Media was then changed every 48 hours until the cells reached 70–80% confluency.
3.1.3

Passaging Adipose Stem Cells
Cells were passaged when they reached 70-80% confluency. A 0.25% Trypsin-

EDTA (Life Technologies 25200-056) was added to the cells and then incubated at 37°C
for 3 minutes for detachment. CCM was added to neutralize the trypsin reaction. The
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contents of the plate were then centrifuged for 1,500 RPM. When centrifugation was
complete the cells were resuspended in CCM. 0.4% Trypan Blue was used to stain the cells
Using a Countess II FL Hemacytometer and a Countess II FL machine, a cell count was
determined. Using the live cell count, cells were plated according to Table 3-1. Media was
changed 24 hours later, and then every 48 hours until cells reached 70–80% confluency.

Table 3-1: Number of cells seeded based upon size of plate/well.

Plate

Number of Cells per

Total Volume of CCM

Plate/Well

3.1.4

10-cm

100,000

10 µL

6-cm

45,000

3 µL

6-well

20,000

2 µL

Transfection
hASCs were transfected when they reached 30-50% confluence with either

negative control or MED12-specific siRNA. Negative control siRNA (5nmol/mL)
(ThermoFisher Scientific 4390843) was combined with an equal amount of 2%
Lipofectamine RNAiMAX reagent (Life Technologies 13778075) in 1X OptiMEM I
solution. This was also completed using a MED12-specific siRNA (5nmol/mL)
(ThermoFisher Scientific s19364). The solutions were added to the cells and incubated for
24 hours before media was replaced with differentiation media.
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3.1.5

Adipogenesis
Adipogenesis was induced in cells once they reached 80% confluency through the

addition of AdipoQual (LaCell LLC LaADM-500) medium. Media was changed every 72
hours until differentiation was complete.

3.2
3.2.1

Characterization

Oil Red O Staining
An Oil Red O stock solution was prepared using 0.5g of solid Oil Red O (VWR

11411-412) and 100mL of 100% isopropanol. An Oil Red O working solution was then
prepared using 3 parts of Oil Red O stock solution per 2 parts of distilled water. The
solution was then filtered through a syringe filter (CELLTREAT 229747) A 10% formalin
solution was then added to the cells and incubated at room temperature for 15 minutes. The
Oil Red O working solution was added, and the cells were incubated for 20 minutes at
room temperature. The cells were viewed using a Cytation 5 BioTek Plate Reader.

3.3
3.3.1

Protein Expression

Protein Extraction
After rinsing with PBS (ThermoFisher Scientific 10010023), cold 1X RIPA lysis

buffer containing protease and phosphatase inhibitor was added to the cells. The cells were
then scraped and rotated for 30 minutes at 4°C, and then centrifuged at 4°C at 12,000 RPM
for 20 minutes. The supernatant was removed and stored at -80°C, while the pellet was
discarded.
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3.3.2

Bradford Protein Assay
A 20% Bradford buffer was made using protein dye and distilled water. Six

standards were mixed using BSA, water, and buffer. Proteins of unknown concentrations
were mixed with buffer and distilled water and were pipetted into a clear bottom 96-well
plate in duplicate. The plate was read using a Cytation 5 BioTek plate reader to determine
the absorbance value of each sample.

3.3.3

Western Blot
Before beginning, a 10% running buffer was made, as well as a 10% Tris/Glycine

buffer, which is stored in the fridge until use. Laemmli buffer (Biorad 1610737), water,
and protein solution was made using the protein concentrations determined from the
Bradford protein assay. The samples were heated at 100°C and then spun down. The
protein samples were loaded into the gel (Biorad 456-1084) and run at 120V for 90 minutes
with a standard for comparison (Bio-Rad, Catalog #1610376).
In order to transfer the protein to the membrane, the following items were
“sandwiched” on top of each other, making sure to pop any bubbles in the process: sponge,
filter paper, PVDF membrane (Biorad 1704156), gel, filter paper, sponge. The gel and
membranes must remain wet with transfer buffer throughout this process. The gel was
transferred at 100V for 60 minutes.
The membrane was then rocked in a non-fat milk (Cell Signaling Technology
99995) blocking buffer for 60 minutes. Using this buffer, primary antibody solutions were
made. After cutting the membrane according to protein size, the membrane pieces were
probed overnight in the fridge.
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The following day, the membranes were washed 5 times with TBST (1X) and then
probed using a secondary antibody solution for 60 minutes. After rinsing 5 more times,
Western ECL reagents were mixed 1:1 and then pipetted onto the surface of the membranes
in the dark due to light sensitivity. Pictures were then taken of the membranes.

3.4
3.4.1

Gene Expression

RNA Collection and Extraction
RNA was collected using Trizol reagent (Thermo Scientific 15596018) following

the manufacturer’s protocol. The cells were then collected and stored at -80°C until
extraction.
Collected RNA was retrieved from -80°C freezer and allowed to thaw at room
temperature. Chloroform was added to each sample. The samples were agitated, incubated
at room temperature, and then centrifuged at 4°C at 12,000 xG. The clear supernatant was
removed, and the phenol waste was discarded. Glycogen (5mg/mL) (ThermoFisher
Scientific R0551) was added to each sample, followed by 100% isopropanol. The samples
were incubated at room temperature and then centrifuged at 4°C at 12,000 xG. The liquid
supernatant was removed, leaving the RNA pellet behind. 75% ethanol was used to wash
the RNA pellet, then the samples were centrifuged again at 4°C at 7,500 xG. The liquid
supernatant was removed and the RNA pellet remained. The pellet was resuspended in
nuclease-free water (VWR 10220-404) and stored at -80°C.
RNA was quantified using a spectroscopy program on a Cytation 5 BioTek Plate
Reader.
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3.4.2

cDNA Synthesis
cDNA was synthesized using 1 µg of RNA, nuclease-free water, and qScriptTM

cDNA SuperMix (Quantabio 95048-100), according to manufacturer’s protocol.

3.5
3.5.1

RT-PCR

RT-PCR
Using GoTaq Green Master Mix (Promega M7122), cDNA, nuclease-free water,

and primers (Table 3-2), PCR was run in a thermal cycler for 30 cycles at 60°C. The
samples were run through an agarose (VWR 97062-250) gel via electrophoresis.
3.5.2

qRT-PCR
qRT-PCR was performed in technical triplicate using PowerUp SYBR Green

Master Mix (Applied Biosystems A25742), nuclease-free water, forward and reverse
primers (Table 3-2), and 1 µL cDNA per reaction in a 96-well plate. The reaction was
run using a StepOnePlusTM Applied Biosystems machine standard quantitation
experiment. The data was plotted on a Comparative CT (ΔΔ CT) curve.
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Primers

Table 3-2: Identification of forward and reverse primers used for RT-PCR and qRTPCR.
Gene

Forward Sequence

Reverse Sequence

Product Size
(bp)

GAPDH

ACTAGGCGCTCACTGTTCTCT

CAATACGACCAAATCCGTTGACT

99

Tubulin1-α

CCAGGGCTTCTTGGTTTTCC

CGCTCAATGTCGAGGTTTCT

267

MED12

CGAAAAGGGACAGCAGAAAC

CCCATCCTCCCCACCTAAGA

87

PPAR-γ

GTGGTACTTTACGCCTCGGT

GCTCGGTTACTCCCCGTTTC

70

CHAPTER 4
CONCLUSIONS AND FUTURE WORK

4.1

Conclusions

Here we sought to investigate the role MED12 plays in cell type-specific gene
expression by studying its role in adipogenesis of human adipose-derived stem cells. Based
on the data shown, MED12 plays a role in the initiation of adipogenesis. However, MED12
does not play as great a role in continuing differentiation. When MED12 expression is
decreased prior to inducing differentiation, adipogenesis is diminished. When we looked
further to determine a more precise role for MED12, we found that delaying the knockdown
and transfecting cells that are already undergoing differentiation resulted in no significant
difference in differentiation potential of the adipose stem cells compared to when MED12
expression was unchanged. Knowing that MED12 initiates cell type-specific gene
expression by binding to Cyclin C and activating the kinase function of CDK8 (Allen &
Taatjes, 2015), then decreasing MED12 expression must inhibit this process by preventing
phosphorylation and downstream events, like differentiation. The results presented in this
thesis suggest that MED12 is crucial to transcription of adipose-specific genes, and when
MED12 expression is diminished, hASCs are unable to differentiate as effectively. The
results presented here support previously published literature as well. Since MED12 is
essential to the activation of CDK8 kinase function, if MED12 was completely absent, it
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is likely that no differentiation would occur at all, compared to the minimal lipid formation
seen when MED12 expression is only decreased. MED12 is key to several developmental
pathways, including, but not limited to, Wnt, β-catenin, and Shh. Interruption of any of
these vital pathways results in severe developmental disability (Straub et al., 2020). It is
evident that MED12 is crucial for growth, and without it, development of the neural crest
(Rau et al., 2006) and, based upon this research, differentiation of hASCs into adipocytes,
would likely be impossible. Tumors would result, as mutated MED12 expression
oftentimes results in uterine (Mäkinen et al., 2017) and breast tumors (Nagasawa et al.,
2015). If MED12 was completely knocked out, lethality would likely be inevitable (J. W.
Yin & Wang, 2014). Therefore, MED12 is essential to cell type-specific gene expression
and proper mammalian development.
The Mediator complex is essential for the proper regulation of cell type-specific
gene expression (Allen & Taatjes, 2015). MED12 in particular is known to act as an
initiator of cell type-specific gene expression by activating the kinase function of CDK8,
without which, propagation of signal cascades would be impossible. Without proper
signaling pathways, gene activation and further differentiation will not occur (Clark et al.,
2015). As we develop an understanding of the role that specific subunits of the complex
play in cell fate determination, we will better be able to control stem cells and ultimately,
provide relief for disorders that are currently deemed incurable.
Adipose-specific genes are activated by direct binding of transcription factors to
DNA. RNA Polymerase II then transcribes these adipose-specific genes, resulting in fat
formation, and ultimately, adipogenesis. However, RNA Polymerase II must be recruited
to the activated genes in order to perform transcription. The Mediator complex is capable
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of modulating the interaction between RNA Polymerase II and cell type-specific genes in
order for adipogenesis to occur (Allen & Taatjes, 2015).
However, as shown previously, the entire Mediator complex plays an important
role in development, with each subunit performing a different function in growth and tissue
repair. MED28 plays a role in peri-implantation as knockout proves fatal in mice (Li et al.,
2015). MED19 controls white adipose tissue development by bridging PPAR-γ and RNA
Polymerase II together for transcription (Dean et al., 2020). And finally, through the data
shown in this paper, MED12 plays an important role in differentiation of hASCs into
adipocytes, providing further evidence to the Mediator complex’s important role in
development.
MED12 is implicated in a number of developmental defects and human disease,
including breast cancers (Nagasawa et al., 2015), uterine fibroids (Turunen et al., 2014),
and even X-linked disorders like Lujan and Opitz–Kaveggia syndromes (Srivastava et al.,
2019). Typically when MED12 is mutated, signals are no longer propagated as effectively,
meaning mutation result and tumors form (Turunen et al., 2014). As people have
recognized the role of MED12 in these conditions, they have recognized MED12 mutation
as the common element. However, no cure for MED12 mutation has yet to be uncovered.
Previous research directing stem cell fate of mesenchymal stem cells into cardiomyocytes
(Choi et al., 2010) and chondrocytes (Stepien et al., 2016) shows the promise behind these
stem cells. If these cells can be induced to form other cells of the mesoderm, then through
gene therapy, adipose tissue, which arises from mesenchymal stem cells, should be able to
be directed to form brown adipose tissue from white adipose tissue through transcription
factor manipulation (Dean et al., 2020). This would effectively reduce the effects of obesity
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on those suffering. If we can determine a way to control MED12 functioning to promote
formation of brown fat and inhibit formation of white fat without resulting in tumor
formation, then it will become possible to control fat formation and prevent obesity-related
illness using gene therapy.

4.2

Future Work

The Mediator complex is highly conserved (Allen & Taatjes, 2015), giving clear
indication to its importance for development and growth of all organisms. Although
MED12 has been shown to initiate cell type-specific gene expression, decreasing its
expression over time does have an effect on adipogenesis, evident by decreased expression
of adipogenic markers when MED12 is knocked down. However, more research needs to
be performed to determine how MED12 knockdown late in adipogenesis affects the
process. It is possible that adipogenic markers compensate for loss of MED12, thereby
continuing the differentiation process even when MED12 is not present. It may be
necessary to perform a double knockdown, by simultaneously knocking down MED12 and
PPAR-γ late in adipogenesis. If adipogenesis is significantly affected, then it is likely that
PPAR-γ compensates for MED12 loss through upregulation. MED12’s effect on
expression of other important proteins, including PPAR-γ, Cyclin C, and CDK8, must be
determined as well. GAPDH expression appears to decrease after diminishing MED12
transcript expression, but Image J analysis needs to be performed to confirm this
phenomenon.
But what actually controls MED12 function remains to be uncovered as well, and
if cell signals released by cells undergoing MED12-initiated differentiation could be
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signals to undifferentiated cells to begin the process. There may be a cascade of events that
result from one cell beginning initiation of cell type-specific gene expression that is simply
continued once these signals are released. By collecting adipogenic media aspirated from
cells after varying timepoints, this conditioned media could be used to induce
differentiation in self-renewing hASCs. While adipose-specific transcription factors are
likely exhausted, the differentiated cells may have released other signals during
adipogenesis that may aid self-renewing cells in differentiation as well. Varying adipogenic
markers, like PPAR-γ, LPL, or even CEBP-α, can be used to confirm that adipogenesis is
occurring and to what extent.
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